atezolizumab
-umab
bococizumab
lucatumumab
agonistic monoclonal antibody
antigenomic
intrabody
alloantibody
cibisatamab
reagin
teplizumab
dorlixizumab
conatumumab
robatumumab
siltuximab
panitumumab
zolimomab
chromobody
sulesomab
antiantibody
immunonaive
biciromab
-a-
drozitumab
olendalizumab
presentation
monoclonal
Forssman antibody
-ab
onartuzumab
oleclumab
polyantibody
heterophil antibody
properdin
iratumumab
heterophile antibody
idiospecific
pancytokeratin
complement
polyvalent
dacetuzumab
sifalimumab
bezlotoxumab
antiustekinumab
Ab
immunoprobe
brentuximab
-i-
lenzilumab
polytypic